Navigation Links
Curbing C. difficile's toxin production
Date:9/5/2007

dY activity, however, indicates to the bacteria that they are lacking key nutrients and that it is time to make the toxins they need to get food from the host cells.

To determine how CodY tells the bacteria not to make toxins, Sonenshein and colleagues removed DNA from the bacteria, and observed the interaction of the DNA and the CodY protein in vitro. They found that CodY targeted the region of the bacterial chromosome that includes the toxin genes. When CodY senses that the cell has enough nutrients, it binds to this gene region, and prevents the bacterium from making toxin, says Sonenshein. Conversely, when food is scarce, the CodY protein does not bind to these genes, allowing C. difficile to make the toxins needed to attack intestinal cells.

Knowing what turns on, and more importantly, what turns off the toxin-producing genes in C. difficile opens the door for treatment and prevention options. It is possible that, based on our findings, a new drug could be developed that would trick CodY into thinking there is enough fuel for the bacteria, causing CodY to remain bound to the toxin gene region and thus suppressing toxin production.


'/>"/>

Contact: Siobhan Gallagher
Siobhan.Gallagher@tufts.edu
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert

Page: 1 2

Related biology news :

1. Defensins neutralize anthrax toxin
2. Green catalyst destroys pesticides and munitions toxins, finds Carnegie Mellon University
3. Tetanus toxin found to have therapeutic properties
4. Structures of marine toxins provide insight into their effectiveness as cancer drugs
5. Prenatal exposure to marine toxin causes lasting damage
6. UCSD study finds anthrax toxins also harmful to fruit flies
7. Scientists design potent anthrax toxin inhibitor
8. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
9. Scientists reveal how deadly toxin hijacks cells
10. Scientists develop a way to make the deadliest toxin known even more toxic
11. Yale researchers find environmental toxins disruptive to hearing in mammals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
(Date:7/11/2014)... from Ume University, Sweden, have explored two different ... reaction sequence leading to the formation of oxygen ... published in the scientific journal Nature Communications ... present day synthetic catalysts for water oxidation, which ... for the direct storage of solar energy in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... 25, 2012  ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... its BluScience ( www.bluscience.com ) line ... McKesson to approximately 4,000 independent drugstores and pharmacies. ...
... five leading causes of death. And yet, despite ... treatment for most cancers. In addition, disappointing results ... the need for alternative methods. Mathematical ... of tumors in terms of differential equations and ...
... Research!America,s Board chair, former Congressman John Edward Porter (R-IL), ... in basic research. , "America,s leadership is at ... in discovery and development," said Porter. "We could ... Europe integrate science and technology into economic growth while ...
Cached Biology News:ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 2ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 3ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 4Aiding cancer therapy by mathematically modeling tumor-immune interactions 2Aiding cancer therapy by mathematically modeling tumor-immune interactions 3State of the Union speech: Promising outlook for research and innovation 2
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced financial ... The net income for the first quarter ended March ... of $14.1 million during the same period in 2010. Net ... related primarily to the $34.2 million in collaboration revenue recognized ...
... 2011 Silence Therapeutics plc (AIM: ... of patent 4,705,370, titled "Further Novel Forms of ...  The issued patent covers aspects of Silence,s platform ... 2,-O-Methyl structures known as AtuRNAi.  Silence,s AtuRNAi molecules ...
... May 2, 2011 Dendreon Corporation (Nasdaq: DNDN ) ... Revenue for the quarter ended March 31, 2011 was $28.1 million ... The GAAP net loss for the quarter ended March ... $125.7 million, or $0.96 per share for the quarter ended March ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 2Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 3Dendreon Reports First Quarter 2011 Financial Results 2Dendreon Reports First Quarter 2011 Financial Results 3Dendreon Reports First Quarter 2011 Financial Results 4Dendreon Reports First Quarter 2011 Financial Results 5
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: